MedImmune LLC

ACTIVE

United Statesmedimmune.comSubsidiary5,001–10,000 employeesEstablished: 1987-01-01

Part of 阿斯利康

Clinical Trials

292

26 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1987

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

147

50.3%

Phase 2

27.7%

Phase 3

8.9%

Phase 4

5.1%

Not Applicable

0.3%

Trial Status Distribution

Active, not recruiting

8.9%

Completed

233

79.8%

Recruiting

0.7%

Suspended

0.3%

Terminated

7.9%

Withdrawn

2.4%

Clinical Trials

Trials sponsored by this organization (292)

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Phase 1

Completed

interventional

Mar 202057 participants

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Phase 1

Completed

interventional

Oct 201939 participants

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

Phase 1

Completed

interventional

Sep 201936 participants

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

Phase 2

Completed

interventional

Sep 201974 participants

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1

Active, not recruiting

interventional

Sep 201961 participants

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Phase 1

Completed

interventional

May 201961 participants

Page 1 of 37

Approvals

Approvals by Agency

CANADA

Health Canada

Approvals

Recent Approvals

News

No news articles found

Back to Organizations